Head-to-head dispatch
Hers vs PauseRX
Two GLP-1 providers, one scorecard. Both are graded on the same six Desk Score dimensions — here is how they stack up, and which one fits you.
Desk Score
Women-focused telehealth brand from Hims and Hers offering compounded semaglutide on a 6-month plan.
Marked down on: Limited public information on program details
FDAWarning letter issued to Hims & Hers Health, Inc. dba Hers in September 2025. See the FDA warning-letter database.
Desk Score
PauseRX is a nationwide compounded GLP-1 telehealth platform notable for its transparency: it names its 503A pharmacy partner (Strive Pharmacy in Gilbert, AZ), its physician network (Beluga Health), and…
Marked down on: States served not listed — site claims nationwide, but you must contact support to confirm availability
Hers takes this head-to-head with the higher Desk Score, 76/100 (C) against 67/100 (C) for PauseRX. PauseRX still holds its ground where its strengths line up with yours.
Desk Score, dimension by dimension
Same six measured dimensions for both. The red flag marks the stronger side. See the methodology.
Hers
76/100
C
PauseRX
67/100
C
Price transparency
State access
Molecule range
Onboarding speed
Support responsiveness
Licensing & trust
The spec sheet
| Field | Hers | PauseRX |
|---|---|---|
| Semaglutide | $199/mo (starting dose, compounded) | $199/mo |
| Tirzepatide | $299/mo (starting dose, plus a separate fee, brand-name) | $249/mo (starting dose, compounded) |
| Coverage | All 50 states | Coverage not published |
| Brand-name | Yes | Yes |
| Oral option | Injectable only | Injectable only |
| Best for | Readers who want mainstream telehealth GLP-1 access. | Readers who want explicit 503A pharmacy and physician-network disclosure. |
| Desk Score | 76/100C | 67/100C |
The verdict
Desk pick — HersHers takes this head-to-head with the higher Desk Score, 76/100 (C) against 67/100 (C) for PauseRX. PauseRX still holds its ground where its strengths line up with yours.
Choose Hers if…
Readers who want mainstream telehealth GLP-1 access.
$199/mo (starting dose, compounded) sema · $299/mo (starting dose, plus a separate fee, brand-name) tirz · All 50 states
FDAWarning letter issued to Hims & Hers Health, Inc. dba Hers in September 2025. See the FDA warning-letter database.
Choose PauseRX if…
Readers who want explicit 503A pharmacy and physician-network disclosure.
$199/mo sema · $249/mo (starting dose, compounded) tirz · Coverage not published
Assume any provider we list may compensate us — we may earn a referral commission at no extra cost to you, and what we file on a provider reads the same either way. Read full breakdowns: Hers · PauseRX.
Also here
CoreAge Rx tops every dispatch at 94/100
Whichever of these two you lean toward, the Desk's #1-rated provider outscores them both. The Desk's top dispatch: flat all-in pricing, both molecules, all 50 states — no teaser-rate traps.
More head-to-heads
- Hers vs CoreAge Rx
- PauseRX vs Vaylen
- Hers vs Strut Health
- PauseRX vs Ondra Health
- Hers vs Invigor Medical
- PauseRX vs Vytora Health
Or see the full comparison hub and the complete ranking.
Pricing and verification reflect each provider's public disclosures at last scoring; the Desk Score is our editorial judgment per the methodology. Prices change — confirm on each provider's own site. Not medical advice; see our disclosure.